DACS
CCCC icon

Dymon Asia Capital (Singapore)’s C4 Therapeutics CCCC Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,250
Closed -$266K – 137
2021
Q4 		$266K Sell
8,250
-8,250
-50% -$326K 0.03% 102
2021
Q3 		$737K Buy
16,500
+7,952
+93% +$341K 0.08% 85
2021
Q2 		$323K Buy
+8,548
New +$306K 0.03% 81

Other funds holding CCCC

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s CCCC Position: Q1 2022 in Review

Dymon Asia Capital (Singapore) sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 8,250 shares — an estimated $266K sold.

Dymon Asia Capital (Singapore) first reported a position in CCCC in Q2 2021 and held it in 3 quarters. The position peaked at $737K in Q3 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Dymon Asia Capital (Singapore) reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 8,250 C4 Therapeutics shares in Q1 2022, an estimated $266K.
  • Dymon Asia Capital (Singapore) first reported a position in C4 Therapeutics in Q2 2021 and held it in 3 quarters.
  • Dymon Asia Capital (Singapore)'s C4 Therapeutics position peaked at $737K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2022, filed 13 May 2022.